Market news

Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de

Palisade Bio (PALI) has obtained clearance from Health Canada for its global phase 2 study evaluatin

Palisade Bio (PALI) said the US Food and Drug Administration cleared its investigational new drug ap

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s diseaseFirst patient dosing targeted for Q1 2027; primary...

Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer, will participate in the Stifel 2026 V

Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory...

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company’s lead candidate, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed...

Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking pla

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.